Fiasp Approval History
Fiasp (insulin aspart) is a rapid-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. Fiasp is a new formulation of NovoLog, in which the addition of niacinamide (vitamin B3) helps to increase the speed of the initial insulin absorption.
Development History and FDA Approval Process for Fiasp
|Sep 29, 2017||Novo Nordisk Receives FDA Approval for Fiasp (insulin aspart injection), a New Fast-Acting Mealtime Insulin|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.